Details of the Drug

General Information of Drug (ID: DM7P1J4)

• Drug Name: Benralizumab

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Approved	[1]
Chronic obstructive pulmonary disease	CA22	Phase 3	[2]

• Affected Organisms: Humans and other mammals
• ATC Code:
  R03DX10: Benralizumab
  R03DX: Other systemic drugs for obstructive airway diseases
  R03D: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
  R03: DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
  R: RESPIRATORY SYSTEM
• Drug Type: Monoclonal antibody
• Sequence:
  >heavy chain
  EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKY
  NERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVS
  SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
  SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
  GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
  NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD
  ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
  WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  >light chain
  DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPS
  RFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIKRTVAAPSVFIFPP
  SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
  LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 775 mgday/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 82 mg/L [3]
  Bioavailability: The bioavailability of drug is 58% [3]
  Clearance: The sytemic clearance of drug is 0.29 L/day []
  Half-life: The concentration or amount of drug in body reduced by one-half in 15 - 18 days [3]
  Metabolism: The drug is metabolized via proteases widely spread in the body []
  Vd: The volume of distribution (Vd) of drug is 0.052-0.093 L/kg [4]
• Cross-matching ID:
  UNII: 71492GE1FX
  DrugBank ID: DB12023
  TTD ID: D02PIO
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 5 receptor alpha (IL5RA)	TTXH9AD	IL5RA_HUMAN	Modulator	[5]
Interleukin-5 (IL5)	TTPREZD	IL5_HUMAN	Modulator	[6]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 12 Disease of the respiratory system
• Disease Class: ICD-11: CA23 Asthma
• The Studied Tissue: Lung tissue
• The Studied Disease: Chronic obstructive pulmonary disease [ICD-11:CA23]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-5 (IL5)	DTT	IL5	6.51E-01	-0.02	-0.11
Interleukin-5 (IL5)	DTT	IL5	1.71E-04	0.12	0.71

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7674).
• [3] Benralizumab--a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.
• [4] Wang B, Yan L, Yao Z, Roskos LK: Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):249-257. doi: 10.1002/psp4.12160. Epub 2017 Jan 21.
• [5] Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8.
• [6] Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma